NeRRe Therapeutics pushes leads by €26m Series B financing
Neuronal hypersensitivity specialist NeRRe Therapeutics has closed an oversubscribed Series B financing round led by Fountain Healthcare Partners.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Bayer antibiotics spin-out Aicuris bags IMI grant
The Innovative Medicines Initiative is pushing clinical development of a novel compound against Gram-negative bugs that cause urinary tract and intra-abdominal infections. Backed by IMI, Aicuris is launching a clinical programme for an antibiotic.
Tiziana joins rheumatoid arthritis race
The London-based immunotherapy specialist Tiziana Life Sciences bagged the license for the human anti-interleukin 6 receptor antagonist NI-1201 from Swiss Novimmune.
Sanofi and Boehringer Ingelheim close ?business swap
French Sanofi is set to become a global market leader in the non-prescription market by acquiring Boehringer Ingelheims consumer healthcare (CHC) business in exchange for Sanofis animal health arm Merial.
IMI launches €348m call
Electronic submission systems of the Innovative Medicines Initiative (IMI) will open for biotech companies and research groups on 4 January 2017 to apply for collaborative projects with pharma partners under the IMI scheme.
Belgian spin-off Indigo challenges diabetes giants
Indigo Diabetes NV has been spun-off from University of Ghent and international research institute imec with a series A financing of €7m. The companys needle-free glucose sensor addresses a €12bn market.
EMA recommends market approval of four biologics
The Europan Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended four biologics, among them three biosimilars, one monoclonal antibody as well as two targeted therapies for EU market authorisation.
Evotec bags US$45m upfront in Celgene deal
Neurology specialist Celgene has nailed down access to Evotecs induced pluripotent stem cell (iPSC) platform for screening of compounds against neurodegenerative diseases.
Grifols confirms €1.75bn acquisition in transplantation safety
Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit.
Oncology: Orion teams up with Wi2
Finnish theranostics specialist Orion Corporation is set to fill its oncology pipeline through a drug development alliance.